

REMARKS

Claims 15-33 are pending. Upon entry of this amendment, claims 15-19, 23-29, and 34-38 will be pending, claims 17-19, 23-26, and 28 having been amended, claims 20-22 and 30-33 canceled, and claims 34-38 added in this amendment.

In claim 19, the term “2-hydroxy-2-propyl” has been replaced with “1-hydroxy-1-methylethyl,” which is the same compound according to IUPAC rules. “2-hydroxy-2-propyl” is the common name for “1-hydroxy-1-methylethyl.”

New claim 34 finds support in the specification, page 16, ll. 17-20, for example. New claim 35 finds support in the specification, page 16, l. 27 – page 17, l. 5, for example. New claim 36 finds support in the specification, page 9, ll. 11-18, for example. New claims 37 and 38 find support in the original claims. Accordingly, there are no issues of new matter.

The specification and the Abstract have been amended to replace the term “2-hydroxy-2-propyl” with “1-hydroxy-1-methylethyl,” as discussed above. Similarly, the term “2-chloro-2-propyl” has been replaced with “1-chloro-1-methylethyl,” which is the same compound according to IUPAC rules. “2-chloro-2-propyl” is the common name for “1-chloro-1-methylethyl.” Accordingly, there are no issues of new matter.

The specification has also been amended to delete the chemical structures on pages 11 and 13. They are inadvertent duplicates of the chemical structures on pages 12 and 14, respectively.

The specification has also been amended on page 11 to correct an inadvertent error. The chemical structures shown on page 12 of the specification are of compounds represented by general formula (3) of the present invention. However, the preceding description on page 11, ll. 3-8, inadvertently refers to these chemical structures as represented by general formula (2). The amendment corrects this error and finds support in general formula (3) and the chemical structures on page 12. Hence, there are no issues of new matter.

Similarly, the specification has been amended on page 13. The chemical structures shown on page 14 of the specification are of compounds represented by

general formula (2) of the present invention. However, the preceding description on page 13, ll. 3-4, inadvertently refers to these chemical structures as represented by general formula (3). The amendment corrects this error and finds support in general formula (2) and the chemical structures on page 14. Hence, there are no issues of new matter.

Examination in light of these amendments is respectfully requested.

The Examiner is invited to contact the undersigned at 202-220-4200 to discuss any matter in connection with this application. The Office is hereby authorized to charge any fees under 37 C.F.R. 1.16 and 1.17 to the Kenyon & Kenyon Deposit Account No. 11-0600.

Respectfully submitted,


Cassandra T. Swain
Cassandra T. Swain, Ph.D.
(Reg. No. 48,361)

Dated: March 8, 2006

KENYON & KENYON LLP
1500 K Street, N.W., Suite 700
Washington, DC 20005-1257

Tel: (202) 220-4200
Fax: (202) 220-4201